术前氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对潜在可切除胰腺癌患者的预后价值
研究纳入103例连续接受术前FDG-PET/CT的潜在可切除胰腺癌患者,评估SUVmax等指标对术后复发的独立预测价值。中位随访23.1个月,多因素分析显示SUVmax(P=0.0163)和CA19-9水平(P=0.0364)独立预测无病生存期。SUVmax<2.5组术后3年DFS为61.9%,显著优于SUVmax≥2.5组的9.7%(P=0.0006)。
要点
- 术前SUVmax≥2.5与可切除胰腺癌术后无病生存期差相关。
- SUVmax<2.5组术后3年DFS为61.9%,SUVmax≥2.5组为9.7%。
- 多因素分析中SUVmax和CA19-9水平独立预测无病生存期。
核心结论
- SUVmax可预测可切除胰腺癌患者的无病生存期,SUVmax<2.5提示预后更好。
研究设计与样本
- 研究纳入103例连续接受术前FDG-PET/CT的潜在可切除胰腺癌患者,采用Cox比例风险模型评估各指标对术后肿瘤复发的独立预测价值,参考标准为术后肿瘤复发(无病生存期)。
诊断标准与关键数值
- SUVmax<2.5组(n=23)术后3年无病生存率为61.9%,SUVmax≥2.5组(n=80)为9.7%(P=0.0006)。
- 单因素分析中SUVmax(P=0.0004)、肿瘤大小(P=0.0002)、T分期(P=0.0102)、N分期(P=0.0049)和CA19-9水平(P=0.0059)与无病生存期显著相关。
- 多因素分析中SUVmax(P=0.0163)和CA19-9水平(P=0.0364)独立预测无病生存期。
临床应用与阅片要点
- 术前FDG-PET/CT测量的SUVmax可用于对潜在可切除胰腺癌患者进行预后分层。
- SUVmax<2.5提示术后无病生存期较好,SUVmax≥2.5提示预后较差。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the prognostic value of preoperative 18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with potentially resectable pancreatic cancer.
METHODS: The study included 103 consecutive patients with potentially resectable pancreatic cancer who underwent preoperative FDG-PET/CT. Age, sex, blood glucose level, tumor marker levels (carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9)), PET-related parameters (maximum standardized uptake value (SUVmax)), and contrast-enhanced CT-related factors (tumor size, location, enhancement pattern, and CT-based T and N factors by tumor nodes metastasis (TNM) classification) were assessed for their ability to independently predict postoperative tumor recurrence using Cox proportional hazards model.
RESULTS: Median follow-up was 23.1 months. Univariate analyses revealed that SUVmax (P = 0.0004), tumor size (P = 0.0002), T factor (P = 0.0102), N factor (P = 0.0049), and CA19-9 levels (P = 0.0059) were significantly associated with disease-free survival (DFS). In multivariate analysis, SUVmax (P = 0.0163) and CA19-9 levels (P = 0.0364) independently predicted DFS. Kaplan-Meier analysis revealed that patients with low (< 2.5) SUVmax had a significantly better prognosis than those with higher SUVmax (P = 0.0006). The DFS in patients with SUVmax < 2.5 (n = 23) and SUVmax ≥ 2.5 (n = 80) was 61.9% and 9.7%, respectively, 3 years postoperatively.
CONCLUSIONS: SUVmax can predict DFS in patients with resectable pancreatic cancer. A SUVmax < 2.5 heralds a better prognosis.
引用
- Omiya Y, Ichikawa S, Satoh Y, et al. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer. Abdom Radiol (NY). 2018. PMID: 30043215. doi:10.1007/s00261-018-1647-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。